Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: A systematic review and meta-analysis by Navarese, Eliano P et al.
Cardiac mortality in patients randomised to
elective coronary revascularisation plus medical
therapy or medical therapy alone: a systematic
review and meta-analysis
Eliano P. Navarese1,2,3*, Alexandra J. Lansky4, Dean J. Kereiakes5, Jacek Kubica1,3,
Paul A. Gurbel6, Diana A. Gorog7,8, Marco Valgimigli9, Nick Curzen10,11,
David E. Kandzari12, Marc P. Bonaca13, Marc Brouwer14, Julia Uminska15,
Milosz J. Jaguszewski16, Paolo Raggi2, Ron Waksman17, Martin B. Leon18,19,
William Wijns20, and Felicita Andreotti21,22
1Interventional Cardiology and Cardiovascular Medicine Research, Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland; 2Faculty
of Medicine, University of Alberta, Edmonton, Canada; 3SIRIO MEDICINE research network, Poland; 4Yale University School of Medicine, New Haven, CT, USA; 5Christ Hospital
and Lindner Research Center, Cincinnati, OH, USA; 6Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, MD, USA; 7Faculty of
Medicine, National Heart and Lung Institute, Imperial College, London, UK; 8Cardiology Department, East and North Hertfordshire NHS Trust, Stevenage, UK; 9Department of
Cardiology, Inselspital Universitätsspital, Bern, Switzerland; 10University Hospital Southampton NHS Foundation Trust, Southampton, UK; 11University of Southampton,
Southampton, UK; 12Department of Interventional Cardiology, Piedmont Heart Institute, Atlanta, GA, USA; 13CPC Clinical Research, University of Colorado School of Medicine,
USA; 14Department of Cardiology, Radboud University Medical Centre, Nijmegen, the Netherlands; 15Department of Geriatrics, Nicolaus Copernicus University, Bydgoszcz,
Poland; 161st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland; 17Section of Interventional Cardiology, MedStar Washington Hospital Center,
Washington, DC, USA; 18Division of Cardiovascular Medicine, Columbia University Irving Medical Center, New York, NY, USA; 19Cardiovascular Research Foundation, New
York, NY, USA; 20The Lambe Institute for Translational Medicine and Curam, National University of Ireland Galway and Saolta University Healthcare Group, Galway, Ireland;
21Direzione Scientifica, Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy; and 22Cardiovascular Medicine, Catholic University Medical School, Rome, Italy
Received 4 March 2021; revised 28 March 2021; editorial decision 11 April 2021; accepted 13 April 2021
Listen to the audio abstract of this contribution.
Aims The value of elective coronary revascularisation plus medical therapy over medical therapy alone in managing stable





From inception through November 2020, MEDLINE, EMBASE, Google Scholar, and other databases were searched
for randomised trials comparing revascularisation against medical therapy alone in clinically stable coronary artery
disease patients. Treatment effects were measured by rate ratios (RRs) with 95% confidence intervals, using ran-
dom-effects models. Cardiac mortality was the pre-specified primary endpoint. Spontaneous myocardial infarction
(MI) and its association with cardiac mortality were secondary endpoints. Further endpoints included all-cause mor-
tality, any MI, and stroke. Longest follow-up data were abstracted. The study is registered with PROSPERO
(CRD42021225598). Twenty-five trials involving 19 806 patients (10 023 randomised to revascularisation plus
medical therapy and 9783 to medical therapy alone) were included. Compared with medical therapy alone, revas-
cularisation yielded a lower risk of cardiac death [RR 0.79 (0.67–0.93), P < 0.01] and spontaneous MI [RR 0.74
(0.64–0.86), P < 0.01]. By meta-regression, the cardiac death risk reduction after revascularisation, compared with
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medical therapy alone, was linearly associated with follow-up duration [RR per 4-year follow-up: 0.81 (0.69–0.96),
P = 0.008], spontaneous MI absolute difference (P = 0.01) and percentage of multivessel disease at baseline
(P = 0.004). Trial sequential and sensitivity analyses confirmed the reliability of the cardiac mortality findings. All-
cause mortality [0.94 (0.87–1.01), P = 0.11], any MI (P = 0.14), and stroke risk (P = 0.30) did not differ significantly
between strategies.
...................................................................................................................................................................................................
Conclusion In stable coronary artery disease patients, randomisation to elective coronary revascularisation plus medical ther-
apy led to reduced cardiac mortality compared with medical therapy alone. The cardiac survival benefit after revas-
cularisation improved with longer follow-up times and was associated with fewer spontaneous MIs.
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Introduction
Coronary artery disease is the most prevalent medical condition
worldwide among individuals 50 years or older in terms of disease
burden, disability, or early death.1 Chronic coronary syndromes en-
compass clinically stable coronary artery disease patients, with or
without acute coronary syndromes (ACS) or coronary revascularisa-
tion procedures in their natural history.2 Compared with medical
Graphical Abstract
Major findings on cardiac mortality reduction with elective coronary revascularisation plus medical therapy vs. medical therapy alone. Abbreviations in
text.
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therapy alone, timely revascularisation of epicardial artery obstruc-
tions with percutaneous coronary intervention (PCI) in patients with
acute ST-segment elevation myocardial infarction (MI) and with cor-
onary artery bypass grafting (CABG) in patients with left ventricular
ejection fraction <35% has been demonstrated to confer survival ad-
vantage.3,4 In clinically stable patients with preserved or moderately
impaired left ventricular systolic function, symptomatic benefit
favouring revascularisation is well known,3 but controversy remains
regarding prognosis. Significant effects on cardiac mortality of one or
the other strategy have not been reported so far. Moreover, no
meta-analysis has comprehensively included data at longest follow-up
for each available study.
The International Study of Comparative Health Effectiveness with
Medical and Invasive Approaches (ISCHEMIA) trial,5 the largest and
most recent randomised comparison of coronary revascularisation
plus medical therapy vs. medical therapy alone in 5179 patients with
stable coronary syndromes and moderate or severe inducible myo-
cardial ischaemia, showed a non-significant difference between the
two strategies for the primary composite endpoint of cardiovascular
death, MI, hospitalisation for unstable angina, heart failure, or resusci-
tated cardiac arrest at a median follow-up of 3.2 years; at 5 years, the
estimated cumulative composite event rates were 16.4% with revas-
cularisation plus medical therapy vs. 18.2% with medical therapy
alone, suggesting potential benefit with revascularisation at longer fol-
low-up; the trial lacked statistical power to be conclusive on cardiac-
related mortality. In the Fractional flow reserve vs. Angiography for
Multivessel Evaluation 2 (FAME-2) study of 888 patients with stable
coronary artery disease and functionally significant stenoses, the
5-year primary endpoint of death/MI/urgent revascularisation was sig-
nificantly reduced, with lower rates of spontaneous MI, in the revas-
cularisation plus medical therapy compared with the medical therapy
alone arm.6
We conducted a meta-analysis of all trials comparing elective cor-
onary revascularisation plus medical therapy vs. medical therapy
alone in patients with preserved or moderately impaired left ven-
tricular ejection fraction to appraise whether revascularisation in add-
ition to medical therapy affects cardiac mortality at longest follow-up.
Methods
Search strategy and selection criteria
To be eligible, studies had to enrol clinically stable coronary artery dis-
ease patients undergoing, by protocol, randomisation to elective revascu-
larisation plus medical therapy or medical therapy alone. Elective
revascularisation was defined as a planned, deferrable, non-urgent/non-
emergent procedure. Studies that enrolled only post-ACS patients had
to include by protocol a myocardial stress test as an additional criterion
of clinical stability, beyond the absence of symptoms or signs of ischaemia
at rest. Studies with a comparator other than medical therapy, or investi-
gating the acute phase of ACS, or focused only on heart failure patients
were excluded. No limits were set for age, comorbidities, study language,
publication status, or publication date.
Established methods recommended by the Cochrane Collaboration
and the Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) statement were used7,8 to include all pertinent evi-
dence. From inception through 28 November 2020, the following
databases were searched: MEDLINE, Cochrane Central Register of
Controlled Trials, EMBASE, Google Scholar, TCTMD (https://www.
tctmd.com/), EuroPCR, ClinicalTrials.gov, and Clinical Trial Results. The
search was kept current by setting up automated reminders from
MEDLINE for new publications. Backward snowballing was performed
and abstracts from major congress proceedings were searched.
Published meta-analyses on the subject were screened, and the data crit-
ically appraised and cross-checked with the original studies. The following
keywords were used: coronary, coronary artery disease, ischaemic heart
disease, revascularisation, medical therapy, and randomised.
Supplementary material online, Table S1 outlines the full electronic
MEDLINE search process.
Two trained investigators (J.U. and D.A.G.) independently abstracted
data on study design, patient characteristics, and clinical outcomes, using
pre-specified data-extraction forms. Accuracy was appraised and any dis-
crepancies were resolved by consensus after discussion with senior inves-
tigators (E.P.N. and F.A.). Non-relevant articles were excluded on the
basis of title and abstract. For each trial, risk of bias was independently
assessed by two investigators (J.U. and D.A.G.) using the revised
Cochrane RoB2 tool involving five domains (randomisation process, devi-
ation from intended interventions, missing outcome data, outcome meas-
urement, and selection of reported results).
Outcome measures
Events at longest reported follow-up were abstracted. Cardiac or cardio-
vascular mortality was the pre-specified primary endpoint. Most studies
(n = 17) reported cardiac, whereas three5,9,10 reported cardiovascular
mortality; these outcomes were considered together and referred to,
briefly, as ‘cardiac mortality’. As stated by the Academic Research
Consortium-2 consensus, cardiac or cardiovascular death is more specific
than all-cause death in relation to devices or procedures.11 Spontaneous
MI was analysed as a secondary endpoint and in association with cardiac
mortality by meta-regression. Further endpoints were all-cause mortality,
any MI, and stroke, as defined in the original studies. Stroke was consid-
ered of ischaemic origin unless otherwise specified.
Data synthesis and statistical analyses
Trial-level data were analysed according to the intention-to-treat prin-
ciple. Rates rather than crude number of events were considered most
appropriate because they incorporate trial duration,12 which was variable
across trials. Rate ratios (RRs) with 95% confidence intervals (CIs) were
used as summary statistics. Continuity correction was applied to trials
reporting no clinical events. Heterogeneity was assessed by the Cochran
Q test and I2 statistic,13,14 with an I2 value of 0% indicating no observed
heterogeneity, up to 25% low heterogeneity, 26–50% moderate hetero-
geneity, and above 50% high heterogeneity. Potential publication bias was
estimated visually and by linear regression.15 For the meta-analyses,
pooled RRs were calculated using the DerSimonian and Laird random-
effects model. Fixed-effect models were performed as sensitivity analyses
in the absence of high heterogeneity. The reliability of the meta-analysis
for the primary endpoint was assessed by a post hoc trial sequential
analysis (TSA) based on random-effects model assumptions,16 with the
cumulative Z-curve of the meta-analysis calculated and plotted against
Lan-DeMets trial sequential monitoring boundaries.
A pre-specified sensitivity meta-analysis was conducted for the primary
endpoint excluding trials that enrolled only post-ACS patients17,18 or
only chronic total occlusions (CTOs),10,19,20 or trials with a per cent use
of CABG in the invasive arm >30%.21–25 An influence analysis omitting
one study at a time was also conducted. Sensitivity analyses for cardiac
death were further performed excluding trials at risk of bias, trials


























..reporting cardiovascular mortality, or trials that could enrol, by protocol,
within 2 months post-ACS (as per exclusion criterion set by the
ISCHEMIA trial). The association between each trial’s follow-up duration
and the RR for cardiac death was investigated by random-effects meta-re-
gression with follow-up time as covariate. Potential treatment-effect
modifiers on cardiac death were further explored by meta-regression,
including absolute per cent difference for spontaneous MI, trial year, per-
centage with multivessel disease and per cent use at randomisation of
antithrombotic agents, statins, beta-blockers, or angiotensin-converting
enzyme (ACE)-inhibitors/angiotensin II receptor blockers (ARBs). Meta-
regression coefficients and corresponding P-values are reported. For
summary estimates, a P <_ 0.05 (two-tailed) was considered statistically
significant. Analyses were conducted using R Project version 4.0.2 for
statistical computing and Comprehensive Meta-Analysis Software 2.0
(Biostat).
Results
Study selection and patient population
Twenty-five trials5,6,9,10,17–49 involving a total of 19 806 clinically sta-
ble patients randomly allocated to elective revascularisation plus
medical therapy (n = 10 023) or medical therapy alone (n = 9783)
were included. The PRISMA flow diagram is shown in Figure 1. The
key characteristics of the included trials are presented in Table 1. The
Studies included in 
qualitave synthesis 
(n= 25)




ACS studies (n= 5)
HF trials (n= 1)
Comparator other than
medical therapy (n=1)





























Figure 1 Study selection. ACS, acute coronary syndrome; HF, heart failure.


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.main inclusion and exclusion criteria and the risk of bias assessment
are reported in Supplementary material online, Tables S2 and S3.
Eligible trials did not include left main lesions, except for the
European Coronary Surgery Study (ECSS)25 (<8%) and Veterans
Administration Cooperative Study (VA) (13%).48 Average follow-up
was 5.7 years (95% CI 3.60–7.76). Overall, 13 trials were at low risk
of bias in all domains, 11 presented some concern, and 1 was at high
risk of bias (Supplementary material online, Table S3). The patterns of
Figure 2 (A) Rate ratios and 95% confidence intervals for cardiac mortality with revascularisation plus medical therapy vs. medical therapy alone.
Size of data markers is proportional to weight in meta-analysis. CI, confidence interval; MT, medical therapy; P-Y, person-years; RR, rate ratio. (B)
Meta-analyses for cardiac death and spontaneous myocardial infarction excluding studies enrolling only post-acute coronary syndrome patients,
chronic total occlusions, and use of coronary artery bypass grafting >30% in the revascularisation plus medical therapy arm. ACS, acute coronary syn-
drome; CABG, coronary artery bypass grafting; CI, confidence interval; CTO, chronic total occlusion; MT, medical therapy; P-Y, person-years; RR,
rate ratio. (C) Meta-regression of rate ratios for cardiac mortality with revascularisation plus medical therapy vs. medical therapy alone in relation to
follow-up duration. Size of data markers is proportional to size of trial. The solid line represents the meta-regression slope of the change in cardiac
death rate ratio for revascularisation plus medical therapy vs. medical therapy alone with increasing length of follow-up. Rate ratios lower than 1 indi-
cate cardiac death reduction with revascularisation. RR, rate ratio; MT, medical therapy.






































medical therapy for trials reporting cardiac mortality are shown in
Supplementary material online, Table S4.
Cardiac mortality
A total of 20 trials including 17 454 patients contributed to the car-
diac mortality outcome. Overall, 456 of 8946 patients (5.09%) rando-
mised to elective revascularisation plus medical therapy vs. 528 of
8508 patients (6.20%) randomised to medical therapy alone died of
cardiac causes. Heterogeneity was low (I2 = 21%). Funnel plot distri-
butions of RRs and Egger’s test indicated absence of publication bias
(Supplementary material online, Figure S1 and Table S5). Cardiac mor-
tality was significantly lower with allocation to revascularisation plus
medical therapy compared with medical therapy alone: RR 0.79
[0.67–0.93], P < 0.01 (random-effects model, Figure 2A). A compar-
able result was observed using a fixed-effect model: RR 0.80 [0.70–
0.90], P < 0.01 (Supplementary material online, Figure S2).
A lower risk of cardiac death with revascularisation plus medical
therapy vs. medical therapy alone persisted after excluding trials
enrolling only post-ACS patients [RR 0.82 (0.73–0.94), P < 0.01], trials
of CTOs [RR 0.80 (0.67–0.95), P < 0.01], and trials with CABG use in
the revascularisation arm >30% [RR 0.83 (0.71–0.98), P = 0.03]
(Figure 2B). In a further sensitivity analysis excluding studies that could
enrol, by protocol, within 2 months post-ACS, the cardiac mortality
benefit of revascularisation plus medical therapy compared with
medical therapy alone was substantially unchanged: RR 0.82 [0.70–
0.96], P = 0.01 (Supplementary material online, Figure S3). The lower
risk of cardiac death with revascularisation plus medical therapy vs.
medical therapy alone was also maintained omitting each study one
at a time (Supplementary material online, Figure S4), omitting the
three studies that reported cardiovascular mortality (Supplementary
material online, Figure S5), or omitting studies presenting a potential
risk of bias [RR 0.76 (0.65–0.87), P < 0.01; Supplementary material
online, Figure S6].
The effect of follow-up duration on risk of cardiac death was
explored by meta-regression: for each 4-year follow-up increase, the
risk of dying from cardiac causes declined significantly by 19% with al-
location to revascularisation plus medical therapy vs. medical therapy
alone [RR 0.81 (0.69–0.96), P = 0.008; Figure 2C]. The inter-trial
Figure 2 Continued.
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Figure 3 (A) Rate ratios and 95% confidence intervals for spontaneous myocardial infarction with revascularisation plus medical therapy vs. medic-
al therapy alone. Size of data markers is proportional to weight in meta-analysis. CI, confidence interval; MI, myocardial infarction; MT, medical ther-
apy; P-Y, person-years; RR, rate ratio. (B) Meta-regression of rate ratios for cardiac mortality with revascularisation plus medical therapy vs. medical
therapy alone in relation to absolute difference in spontaneous myocardial infarction. Size of data markers is proportional to size of trial. The solid
line represents the meta-regression slope of the change in cardiac death rate ratio for revascularisation plus medical therapy vs. medical therapy alone
across increasing absolute differences for myocardial infarction. Rate ratios lower than 1 indicate cardiac death reduction with revascularisation. MI,
myocardial infarction; RR, rate ratio; MT, medical therapy.
































































































variance for the cardiac mortality outcome appeared to be entirely
attributable to length of follow-up, with an adjusted R2 = 100%.
The percentage of multivessel disease was found, by meta-regres-
sion, to predict greater cardiac death reduction with revascularisation
plus medical therapy compared with medical therapy alone (beta =
-0.006, P = 0.004; Supplementary material online, Figure S7A). The per
cent use of the most frequently employed drug types, i.e. antithrom-
botic agents (P = 0.27), statins (P = 0.71), beta-blockers (P = 0.91), or
ACE-inhibitors/ARBs (P = 0.12), did not significantly influence the ef-
fect of revascularisation vs. medical therapy alone on the risk of car-
diac death, nor did study year (P = 0.16; Supplementary material
online, Figure S7B–F). The inter-trial variance for the cardiac mortality
outcome was not attributable to medical therapy (R2 = 0%).
On TSA, crossing of the cumulative Z-curve into both the trad-
itional boundaries for statistical significance and the trial sequential
monitoring boundary for benefit indicated that a sufficient level of evi-
dence was reached to demonstrate superiority of revascularisation
plus medical therapy over medical therapy alone in reducing cardiac
mortality (Supplementary material online, Figure S8).
All-cause mortality
A total of 23 trials involving 19 260 patients contributed to the ana-
lysis of all-cause mortality. Overall, 1234 of 9745 patients (12.66%)
randomised to elective revascularisation plus medical therapy vs.
1276 of 9515 (13.41%) randomised to medical therapy alone died of
any cause. Heterogeneity was absent (I2 = 0%). There was evidence
of publication bias on visual inspection and by Egger’s test
(Supplementary material online, Figure S9 and Table S5). Overall, no
significant difference in all-cause mortality was observed between
treatment arms using the random-effects [RR 0.94 (0.87–1.01),
P = 0.11; Supplementary material online, Figure S10] or a fixed-effect
[RR 0.93 (0.86–1.01), P = 0.08; Supplementary material online, Figure
S11] model. We investigated potential reasons for publication bias by
excluding the trial at highest risk, given a 66% crossover rate from
medical therapy to revascularisation;48 this resulted in absence of
publication bias (Egger’s P = 0.14) and in a significant 10% all-cause
mortality reduction for revascularisation plus medical therapy over
medical therapy alone: RR 0.90 [0.83–0.99], P = 0.03 (Supplementary
material online, Figure S12).
Myocardial infarction
A total of 20 trials involving 17 168 patients contributed to the ana-
lysis of spontaneous MI. Overall, 572 of 8701 patients (6.57%) rando-
mised to elective revascularisation plus medical therapy vs. 746 of
8467 patients (8.81%) randomised to medical therapy alone experi-
enced a spontaneous MI. Heterogeneity was low (I2 = 21%). Funnel
plot inspection and Egger’s test indicated absence of publication bias
(Supplementary material online, Figure S13 and Table S5). Compared
with medical therapy alone, revascularisation plus medical therapy
yielded a significantly lower risk of spontaneous MI, with an RR of
0.74 [0.64–0.86], P < 0.01 (Figure 3A). Consistent results were
observed using a fixed-effect model (Supplementary material online,
Figure S14). The association between absolute difference for spontan-
eous MI and risk of cardiac death was explored by meta-regression:
the risk of cardiac death with revascularisation plus medical therapy
vs. medical therapy alone declined significantly [RR 0.86 (0.78–0.96),
P = 0.01] for each 3% absolute reduction of spontaneous MI
(Figure 3B). A lower risk of spontaneous MI favouring revascularisa-
tion plus medical therapy vs. medical therapy alone persisted after
excluding specific settings: post-ACS [RR 0.75 (0.67–0.84), P < 0.01],
CTOs [RR 0.74 (0.63–0.86), P < 0.01], and bypass use >30% [RR 0.78
(0.64–0.94), P = 0.01] (Figure 2B).
A total of 20 trials including 17 168 participants contributed to the
results of any MI (procedural or spontaneous). Funnel plot distribu-
tions of RRs and Egger’s test indicated absence of publication bias
(Supplementary material online, Figure S15 and Table S5).
Heterogeneity was high (I2 = 54%). Overall, 787 of 8701 patients
(9.04%) allocated to revascularisation plus medical therapy vs. 849 of
8467 (10.02%) allocated to medical therapy alone experienced an MI
episode, with no significant difference between treatment arms: RR
0.87 [0.73–1.05], P = 0.14 (Supplementary material online, Figure
S16). Procedural MI was sparsely and heterogeneously reported
(Supplementary material online,Table S2). By definition, rates of pro-
cedural MI were higher with revascularisation plus medical therapy
compared with medical therapy alone [RR 2.13 (1.27–3.58),
P < 0.01]. Heterogeneity was high (I2 = 57%), likely driving the high
heterogeneity for any MI. By meta-regression, unlike spontaneous MI,
the absolute difference in procedural MI did not impact cardiac death
(beta = -0.14; P = 0.16; Supplementary material online, Figure S17).
Stroke
A total of 13 trials involving 14 882 patients contributed to the ana-
lysis of stroke. Overall, 170 of 7588 patients (2.24%) receiving elect-
ive revascularisation plus medical therapy vs. 131 of 7294 (1.80%)
receiving medical therapy alone suffered a stroke. Heterogeneity was
moderate (I2 = 27%). The risk for stroke did not differ significantly be-
tween strategies: RR 1.18 [0.86–1.60], P = 0.30 (Supplementary ma-
terial online, Figure S18). The fixed-effect model yielded comparable
results (Supplementary material online, Figure S19). Funnel plot distri-
bution of RRs and Egger’s test indicated absence of publication bias
(Supplementary material online, Figure S20 and Supplementary ma-
terial online, Table S5).
Discussion
The main new findings of the present meta-analysis comparing elect-
ive revascularisation plus medical therapy to medical therapy alone in
a total of 19 806 clinically stable coronary artery disease patients
(17 454 for the cardiac mortality outcome) are at least three-fold.
First, a significantly lower risk of cardiac death was observed among
patients randomised to revascularisation plus medical therapy com-
pared with medical therapy alone. Of note, trial chronological order
did not impact the findings and overall heterogeneity was low.
Second, the cardiac survival benefit of revascularisation plus medical
therapy increased progressively over time, with an incremental rela-
tive risk reduction of 19% for every 4 years of follow-up extension.
Third, there was an association between the reduced risk of cardiac
death and the difference between treatment arms in spontaneous MI.
The cardiac survival benefit of revascularisation was enhanced by
increasing percentages of multivessel disease across trials. Major find-
ings on cardiac mortality reduction with revascularisation plus medic-
al therapy vs. medical therapy alone are displayed in the Graphical
Abstract.
































































































Compared with medical therapy alone, timely coronary revascu-
larisation is known to offer survival advantage in patients with ST-seg-
ment elevation ACS.3 Similarly, clinically stable patients with a recent
ACS might derive enhanced benefit from revascularisation in addition
to medical therapy, compared with other chronic coronary syn-
drome patients. In a sensitivity analysis excluding trials that, by proto-
col, could enrol patients within 2-month post-ACS, we found that
the cardiac mortality benefit of revascularisation remained substan-
tially unchanged.
On meta-regression, longer follow-up was associated with an in-
cremental cardiac survival benefit after randomisation to a revascu-
larisation strategy. Remarkably, the totality of inter-trial variance in
cardiac mortality was attributable to variability in length of follow-up
(R2 = 100%). Thus, the magnitude of cardiac mortality reduction
appeared to be a function of both revascularisation and follow-up
duration. Possible reasons for incremental cardiac survival benefits at
longer follow-ups include: durable benefits of revascularisation in
contrast to attenuation of medical adherence over time; fewer spon-
taneous MIs, and temporal dilution of early procedural complications
following revascularisation.
The risk of spontaneous MI was significantly reduced in the revas-
cularisation plus medical therapy arm compared with medical therapy
alone. In contrast, the risk of any MI (procedural and spontaneous)
did not differ significantly between treatments. We observed an asso-
ciation between reduction of spontaneous MI and reduced risk of
cardiac death, offering a mechanistic understanding of the underpin-
nings for the cardiac death reduction observed with revascularisation
plus medical therapy compared with medical therapy alone. In a pre-
vious analysis of trials comparing revascularisation plus medical ther-
apy to medical therapy alone in chronic and ACS patients,
spontaneous MI was found to predict cardiovascular death.50 In
ISCHEMIA, spontaneous MI events using either primary or secondary
definitions during a 5-year follow-up (i.e., well beyond the dual anti-
platelet therapy period in the revascularisation arm) were significantly
more frequent with medical therapy alone and associated with subse-
quent cardiovascular death.51 Evidence indicates an association be-
tween extent of myocardial ischaemia and risk of cardiovascular
events, as well as between coronary atherosclerotic burden and ad-
verse prognosis.3 Our meta-regression supports this, as the percent-
age of multivessel disease at baseline was found to enhance the
cardiac survival benefit of revascularisation plus medical therapy com-
pared with medical therapy alone.
In the present meta-analysis, all-cause mortality was not significant-
ly different after elective revascularisation plus medical therapy com-
pared with medical therapy alone. Although directionally consistent,
the strong cardiac, but non-significant all-cause, survival signal follow-
ing revascularisation plus medical therapy can be attributed, at least in
part, to opposing directions of cardiac vs. non-cardiac mortalities50:
whereas cardiac mortality declined compared with medical therapy
alone, deaths other than cardiac were bound to accrue over time (as
total death rates will ultimately reach 100% regardless of treatment).
Long-term all-cause mortality tends to be biased towards the null,
based on competing risks that are not influenced by the interventions
being studied and on the uncontrolled effects of care received late
following study interventions.52 The competing risk of non-cardiovas-
cular modes of death, which may blunt the effect of revascularisation
on all-cause mortality, becomes amplified with longer follow-up,
limiting the reliability of all-cause mortality as a main endpoint.52
Additionally, one relatively large and extended trial with a particularly
high (66%) crossover from medical therapy alone to revascularisation
plus medical therapy may have blunted a potential all-cause mortality
benefit of revascularisation. Indeed, in a sensitivity analysis excluding
the above trial, a significant reduction in all-cause mortality emerged
favouring revascularisation, presumably driven by the reduced risk of
cardiac death, which accounted for 39% of all deaths. Stroke risk did
not differ significantly with revascularisation plus medical therapy vs.
medical therapy alone.
Sensitivity meta-analyses excluding studies conducted entirely in
post-ACS patients or entirely for CTOs or with CABG use >30% in
revascularised patients confirmed the significant reduction of cardiac
mortality following revascularisation plus medical therapy compared
with medical therapy alone. Deleting each included trial in turn did
not result in significant deviations from the original overall estimate,
indicating that the overall association of cardiac mortality reduction
with revascularisation plus medical therapy is sound.
By current standards, medical management in older trials was sub-
optimal and, it has been argued, may have favoured elective revascu-
larisation plus medical therapy over medical therapy alone. In each
trial, however, both treatment arms received medical therapy, which
was generally comparable, preserving the capacity to assess the role
of revascularisation on top of standard medical treatment. In the pre-
sent analysis, the per cent use of any of the more frequently
employed drug types, such as statins, antithrombotic agents, beta-
blockers or ACE-inhibitors/ARBs, and study year did not influence
the cardiac mortality findings, nor did any of the different drug types
explain the variance of effect across trials (R2 = 0%). A recent pooled
analysis of trials in patients with diabetes showed a significant reduc-
tion of the composite of death, MI, and stroke with revascularisation
plus medical therapy vs. medical therapy alone that accrued over
time.53 In that analysis, the benefit of revascularisation plus medical
therapy was attenuated when lipid-lowering was suboptimal.53 Thus,
the benefits of revascularisation and of optimised medical therapy ap-
pear additive and the combination may be required to achieve max-
imal and durable prevention of adverse events.54
The findings of this meta-analysis may be insightful when interpret-
ing the results of the ISCHEMIA trial, the largest and most recent
comparing revascularisation plus medical therapy vs. medical therapy
alone in patients with stable ischaemic syndromes. In that study, cor-
onary revascularisation with percutaneous intervention or bypass
grafting plus medical therapy did not significantly improve the primary
composite endpoint nor reduce cardiovascular mortality at a median
follow-up of 3.2 years. However, the primary endpoint time-to-event
curves for the two treatment arms crossed at2 years and then con-
tinued to diverge in favour of revascularisation plus medical therapy.
Although ISCHEMIA was underpowered to conclude on single hard
endpoints, a signal for reduced cumulative cardiovascular death at
5 years in favour of revascularisation plus medical therapy was pre-
sent, with a 1.3% absolute reduction. None of the trials was powered
for cardiac mortality. The present meta-analysis allows less frequent
events such as cardiac mortality to be estimated in a powered
fashion.
Our analysis differs from a recent one, which did not observe a
cardiac mortality reduction after elective coronary revascularisation
plus medical therapy compared with medical therapy alone.55 In that
































































































analysis, longest follow-up times were not always considered; a lower
number of pertinent trials was included, and the impact of follow-up
duration as treatment-effect modifier was not explored in depth.55
We expanded upon this previous analysis to encompass the longest
and broadest randomised evidence comparing elective revascularisa-
tion plus medical therapy to medical therapy alone in clinically stable
patients, after excluding predefined subgroups with proven benefits
from revascularisation. By pooling data at longest follow-up, expand-
ing sample size, focusing on follow-up duration, extracting homoge-
neous modes of death from included trials and exploring plausible
causal relations, the present meta-analysis shows a robust and con-
sistent reduction of cardiac mortality in favour of elective coronary
revascularisation plus medical therapy, directly associated with dur-
ation of follow-up and with lower risk of spontaneous MI.
Limitations
Trial-level data were included. However, consistency between the
overall and the sensitivity analyses supports the robustness of the
findings. Deleting each trial in turn did not produce significant devia-
tions from the original overall estimate. Plausibility is supported by
the meta-regressions associating cardiac mortality benefits with
length of follow-up and with absolute risk difference for spontaneous
MI. Trial sequential analysis confirmed reliability of the meta-analysis.
Crossover from medical therapy alone to revascularisation plus med-
ical therapy may have diluted the effect of revascularisation.56 High
heterogeneity observed for any MI was likely driven by heteroge-
neous reporting and definitions of procedural MI. Heterogeneity
across studies in the per cent use and type of coronary stents, and
lack of individual patient data, prevent a precise characterisation of
stent effects on outcomes. Similarly, lack of outcome data stratified
by number and type of diseased vessels prevents precise character-
isation of disease extent on outcomes, although an association be-
tween cumulative percentage of multivessel disease at baseline and
cardiac survival benefit of revascularisation was found.
Conclusions
The present large-scale analysis of randomised trials shows a signifi-
cant and consistent reduction of cardiac mortality in favour of elect-
ive coronary revascularisation plus medical therapy compared with
medical therapy alone in stable coronary artery disease patients, the
magnitude of which is directly associated with duration of follow-up
and a lower risk of spontaneous MI. Lower cardiac mortality with
revascularisation plus medical therapy was confirmed in all sensitivity
analyses performed. The findings have direct implications for elective
cardiac catheterisation procedures in stable patients with docu-
mented coronary artery disease. Recommendations for medical ther-
apy alone based on trials with limited follow-up have likely
underestimated the benefits of revascularisation plus medical
therapy.
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